Adocia, a biotechnology company specializing in the development of ‘best-in-class’ medicines from already approved therapeutic molecules, in particular proteins and oncologic drugs, has been granted two patents. The first patent is granted in Japan for the BioChaperone PDGF composition and the second in the United States for the BioChaperone polymer. Both patents will protect Adocia’s findings in the field of chronic wound healing, especially for diabetic foot ulcers.
Read the original post:
Adocia’s diabetic foot ulcer treatment receives Japanese and US patents